May 24, 2022 / 01:15PM GMT
Laura Sutcliffe - UBS Investment Bank, Research Division - Equity Research Analyst
All right. Good morning, everyone. Welcome back to day 2 of the UBS Global Healthcare Conference. My name is Laura Sutcliffe, I am a pharmaceuticals analyst here at UBS. And it's my great pleasure to have with me this morning, Dr. Kimberly Smith, who is the Head of R&D at ViiV Healthcare, which most of you will know is GSK's HIV business, although, of course, it's a JV with Pfizer and Shionogi.
So Kim, welcome. It would be great if you could start just by talking -- just introducing yourself and talking a little bit about kind of where you're leading the HIV business at GSK at the moment, and then we'll get stuck into some more detailed questions.
In the audience, if you have questions, please scan the QR code. You're just a couple of clicks away from appearing on this iPad, and we'll get your questions answered.
Kimberly Smith - ViiV Healthcare Limited - Head of Global Research & Medical Strategy
Excellent. So as Laura said, I'm head of R&D for ViiV
GSK plc at UBS Global Healthcare Conference Transcript
Feb 10, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers